process
compris
sizeexclus
chromatographi
sec
anionexchang
chromatographi
aec
investig
downstream
process
cell
culturederiv
influenza
viru
human
influenza
viru
propag
serumfre
medium
use
mdck
cell
host
concentr
viru
prepar
clarifi
inactiv
cell
cultur
supernat
crossflow
ultrafiltr
describ
sec
sepharos
ff
result
averag
product
yield
base
hemagglutin
ha
activ
product
maxim
column
volum
cv
concentr
per
hour
yield
reduct
total
protein
host
cell
dna
hcdna
respect
aec
sepharos
q
xl
use
separ
hcdna
viru
salt
concentr
sodium
chlorid
product
yield
achiev
load
khauml
resin
reduct
hcdna
split
peak
elut
bimod
particl
volum
distribut
suggest
aggreg
virion
coelut
hcdna
constant
amount
hcdna
per
dose
indici
associ
virion
hcdna
overal
product
yield
achiev
total
protein
reduc
hcdna
process
estim
dose
volum
ha
activ
predict
protein
content
limit
human
vaccin
reduct
hcdna
found
insuffici
ng
per
dose
requir
optim
aec
addit
purif
step
oper
select
scalabl
independ
viru
strain
render
process
suitabl
vaccin
product
biotechnol
bioeng
c
nacl
c
nacl
figur
select
sepharos
q
ff
q
xl
viru
hcdna
column
load
column
volum
cv
secpurifi
viru
condit
nacl
linear
gradient
run
nacl
calcul
conduct
flowthrough
eluat
fraction
analyz
ha
activ
hcdna
coelut
hcdna
observ
chromatographi
media
split
peak
elut
case
q
xl
suggest
two
viru
popul
possibl
associ
viru
hcdna
influenza
diseas
impact
everi
year
world
popul
million
peopl
gerdil
infect
caus
influenza
b
virus
lipidenvelop
rna
virus
belong
orthomyxovirida
famili
vaccin
attenu
inactiv
virus
viral
compon
princip
mean
prophylaxi
human
also
veterinari
use
tradit
influenza
viru
propag
fertil
chicken
egg
even
largescal
product
bardiya
bae
year
ago
mammalian
cell
propos
altern
viru
replic
either
use
mdck
tree
et
al
vero
kistner
et
al
cell
pau
et
al
similarli
product
vaccin
mammalian
cell
exampl
rabi
kumar
et
al
japanes
enceph
sugawara
et
al
report
viral
vector
gene
therapi
routin
produc
mammalian
packag
cell
line
segura
et
al
transfiguracion
et
al
precipit
method
concentr
purif
influenza
viru
among
first
describ
cox
et
al
use
gradient
densiti
centrifug
zonal
ultracentrifug
introduc
largescal
prepar
reimer
et
al
reimer
et
al
time
influenza
viru
still
exclus
propag
allantoi
fertil
chicken
egg
even
today
use
densiti
gradient
centrifug
seem
common
product
eggderiv
cell
culturederiv
influenza
vaccin
bardiya
bae
recent
use
crossflow
ultrafiltr
becom
popular
ultrafiltr
cell
culturederiv
influenza
viru
demonstr
result
high
concentr
factor
product
yield
oper
appropri
condit
kalbfuss
et
al
nayak
et
al
first
public
purif
bacteriophag
sizeexclus
chromatographi
sec
control
pore
glass
cpg
date
back
geschwend
et
al
heyward
et
al
use
specif
design
cpg
pore
purif
influenza
viru
precipit
polyethylen
glycol
recent
applic
sec
report
turkey
coronaviru
loa
et
al
pseudotyp
vesicular
stomat
viru
transfiguracion
et
al
moloney
murin
leukemiaderiv
retroviru
segura
et
al
equin
influenza
viru
nayak
et
al
common
studi
recoveri
virion
void
volum
pore
size
chromatographi
media
chosen
exclud
viru
wherea
sec
seem
effici
remov
small
solut
protein
separ
host
cell
dna
hcdna
often
remain
difficult
may
due
size
genom
hcdna
fragment
see
discuss
also
due
associ
virion
hcdna
low
hcdna
burden
admit
product
pharmaceut
use
typic
requir
incorpor
dedic
purif
step
one
common
approach
seem
digest
hcdna
nucleasetreat
transfiguracion
et
al
studi
hcdna
precipit
select
prepar
polioviru
use
protamin
sulphat
adenoviru
use
cation
deterg
amosenko
et
al
goerk
et
al
kumar
et
al
report
clearanc
hcdna
cell
culturederiv
rabi
vaccin
use
second
densiti
gradient
centrifug
step
knudsen
et
al
evalu
remov
hcdna
adsorpt
anionexchang
membran
oper
flowthrough
mode
processscal
purif
antibodi
interestingli
ionexchang
chromatographi
also
mention
context
commerci
influenza
vaccin
brand
et
al
howev
detail
downstream
process
given
studi
suitabl
sec
follow
anionexchang
chromatographi
aec
investig
prepar
human
influenza
vaccin
diafiltr
step
aec
requir
desalt
final
concentr
assum
realiz
fig
concentr
human
influenza
viru
prepar
crossflow
ultrafiltr
describ
kalbfuss
et
al
use
concentr
differ
sec
media
sepharos
sepharos
ff
sepharos
ff
superdex
pg
test
abil
separ
viru
protein
hcdna
separ
investig
closer
detail
sepharos
ff
function
column
load
four
independ
batch
process
condit
deriv
load
studi
select
two
aec
media
sepharos
q
ff
sepharos
q
xl
viru
hcdna
compar
sepharos
q
xl
use
adsorb
hcdna
secpurifi
viru
neg
mode
ie
viru
flowthrough
identif
optim
salt
concentr
batch
adsorpt
experi
product
yield
basi
hemagglutin
ha
activ
report
chromatographi
step
remov
protein
hcdna
report
wherev
appropri
concentr
product
fraction
chromatographi
oper
two
batch
analyz
sdspage
agaros
gel
electrophoresi
particl
volum
distribut
determin
dynam
light
scatter
analysi
viru
concentr
prepar
describ
kalbfuss
et
al
human
influenza
viru
nibsc
unit
kingdom
code
propag
roller
bottl
serumfre
medium
excel
mdck
jrh
bioscienc
unit
kingdom
cat
figur
investig
downstream
process
suitabl
sizeexclus
chromatographi
sec
follow
anionexchang
chromatographi
aec
prepar
human
influenza
vaccin
investig
sec
fed
concentr
cell
culturederiv
human
influenza
viru
obtain
crossflow
ultrafiltr
clarifi
inactiv
cell
cultur
supernat
kalbfuss
et
al
diafiltr
step
aec
requir
desalt
final
concentr
includ
realiz
use
mdck
cell
host
ecacc
unit
kingdom
code
cell
cultur
supernat
clarifi
combin
depth
membran
filter
mm
polypropylen
mesh
mm
polyethersulfon
membran
ge
infrastructur
unit
state
viru
inactiv
chemic
bpropiolacton
mm
ph
incub
h
inactiv
supernat
concentr
crossflow
ultrafiltr
polysulfon
hollowfib
cutoff
ge
healthcar
sweden
concentr
either
frozen
later
use
scout
experi
process
immedi
stabil
ha
activ
investig
titrat
inactiv
supernat
differ
ph
use
sodium
hydroxid
hydrochlor
acid
stir
beaker
ph
measur
electrod
record
reaction
titrat
supernat
incub
h
room
temperatur
neutral
immedi
afterward
neutral
supernat
analyz
ha
activ
test
stabil
respect
salt
ml
phospat
buffer
mm
ph
contain
differ
concentr
sodium
chlorid
nacl
mix
ml
secpurifi
viru
mm
nacl
ph
microtit
plate
plate
incub
h
room
temperatur
incub
ml
reaction
transfer
sampl
tube
dilut
appropri
phosphat
buffer
reduc
concentr
nacl
mm
dilut
reaction
anaylz
ha
activ
batch
adsorpt
conduct
microtit
plate
unus
sepharos
q
xl
resin
ge
healthcar
bioscienc
sweden
wash
water
three
time
adjust
approxim
volum
fraction
graduat
cylind
eighti
microlit
resin
slurri
approxim
ml
pack
volum
mix
ml
phosphat
buffer
mm
ph
contain
differ
concentr
nacl
next
step
ml
secpurifi
viru
dissolv
mm
nacl
mm
phosphat
buffer
ph
ad
well
result
final
volum
ml
plate
incub
thermomix
comfort
eppendorf
germani
h
room
temperatur
shake
rpm
incub
ml
reaction
transfer
sampl
tube
dilut
appropri
phosphat
buffer
reduc
concentr
nacl
mm
dilut
sampl
anaylz
ha
activ
hcdna
content
ktaexplor
use
column
chromatographi
sec
media
sepharos
sepharos
ff
sepharos
ff
superdex
pg
pack
xk
tricorn
column
aec
media
pack
tricorn
column
first
experi
ionexchang
conduct
hitrap
screen
column
ge
healthcar
bioscienc
sweden
void
volum
determin
bsacoat
latex
bead
diamet
postnova
analyt
landsberg
germani
estim
viruscontain
peak
pack
bed
column
test
regularli
determin
asymmetri
hetp
aceton
vv
dissolv
eluent
specif
column
summar
tabl
column
sanit
sodium
hydroxid
least
h
experi
column
store
vv
ethanol
room
temperatur
feed
materi
ie
viru
concentr
pool
sec
eluat
fraction
inject
use
ml
superloop
ge
healthcar
bioscienc
sweden
eluat
either
fraction
fraction
collector
ge
healthcar
bioscienc
sweden
use
outlet
valv
chromatographi
system
sec
run
conduct
constant
flow
rate
cmh
use
phosphat
buffer
mm
ph
contain
nacl
eluent
complet
batch
process
automat
multipl
injectionelut
cycl
product
fraction
run
pool
load
onto
aec
column
present
k
av
elut
volum
column
volum
instead
elut
volum
retent
time
prefer
scout
experi
better
compar
chromatographi
media
area
normal
concentr
ie
densiti
distribut
instead
absolut
concentr
use
plot
ha
activ
dna
total
protein
area
curv
compar
differ
analyt
aec
run
oper
constant
flow
rate
cmh
eluent
sec
use
equilibr
column
wash
unbound
feed
materi
viru
collect
flowthrough
adsorb
hcdna
impur
desorb
salt
gradient
nacl
column
clean
afterward
mixtur
hydrochlor
acid
sodium
chlorid
follow
mixtur
sodium
chlorid
sodium
hydroxid
min
contact
time
min
contact
time
respect
analyt
method
perform
previous
describ
kalbfuss
et
al
wickramasingh
et
al
briefli
total
protein
quantit
colorimetr
use
coomassi
dyebind
assay
hcdna
quantit
fluoresc
enhanc
picogreen
upon
bind
doublestrand
dna
product
fraction
chromatograph
purif
step
analyz
sdspage
agaros
gel
electrophoresi
particl
volum
distribut
obtain
dynam
light
scatter
analysi
refract
index
dynam
viscos
determin
sec
eluent
mm
nacl
mm
phosphat
buffer
ph
ha
activ
serv
measur
viru
content
improv
assay
format
involv
measur
light
extinct
nm
nonlinear
regress
gave
rise
analyt
error
confid
interv
ha
activ
measur
immedi
experi
sinc
freez
phosphat
buffer
led
signific
loss
activ
due
unavail
refer
antigen
calibr
elisa
srid
measur
could
establish
concentr
hemagglutinin
protein
therefor
estim
ha
activ
content
calcul
assumpt
one
virion
bound
per
erythrocyt
agglutinationendpoint
donald
isaac
accord
composit
virion
report
knipe
howley
total
protein
mass
influenza
virion
sum
gmol
fraction
hemagglutinin
protein
determin
eggderiv
oxford
et
al
good
agreement
theoret
deriv
base
calcul
valu
knipe
howley
data
shown
sinc
concentr
erythrocyt
use
assay
adjust
ml
viru
particl
concentr
estim
accord
n
v
ha
hau
ml
ml
ha
specif
ie
per
volum
ha
activ
use
avogadro
number
convers
total
protein
mass
virion
mass
fraction
hemagglutinin
mass
concentr
hemagglutinin
estim
c
ha
n
v
mol
g
mol
specif
ha
activ
ml
thu
correspond
mass
concentr
ngml
sec
oper
group
separ
mode
separ
void
fraction
retard
molecul
scout
experi
column
pack
sepharos
sepharos
ff
sepharos
ff
superdex
pg
load
column
volum
cv
viru
concentr
produc
crossflow
ultrafiltr
batch
use
uv
absorb
nm
record
onlin
eluat
fraction
coars
analyz
offlin
ha
activ
total
protein
hcdna
fig
uv
trace
run
show
two
distinct
peak
correspond
k
av
void
volum
small
solut
data
shown
peak
uv
trace
reach
baselin
accord
offlinemeasur
ha
activ
partial
retent
viru
popul
occur
sepharos
largest
pore
size
media
viru
elut
exclus
void
volum
protein
hcdna
elut
two
peak
detect
uv
monitor
shift
observ
larger
smaller
k
av
decreas
pore
size
chromatographi
medium
case
superdex
pg
smallest
pore
size
almost
separ
viru
protein
hcdna
occur
viral
host
cell
protein
distinguish
protein
assay
use
correl
ha
activ
total
protein
first
fraction
run
sepharos
sepharos
ff
howev
suggest
assay
mainli
detect
viral
protein
fraction
accord
correl
best
separ
viru
impur
achiev
sepharos
nevertheless
sepharos
ff
chosen
prepar
run
sinc
elut
viru
occur
exclus
void
volum
elut
void
volum
lead
narrow
peak
absenc
mass
transfer
spread
due
size
distribut
viru
popul
henc
less
dilut
product
addit
sepharos
ff
rigid
sepharos
therefor
better
handl
easier
column
pack
higher
flow
rate
next
step
column
load
inject
volum
optim
good
compromis
product
puriti
product
column
load
cv
use
viru
concentr
batch
uv
absorb
record
nm
fraction
eluat
analyz
offlin
fig
total
protein
concentr
consid
optim
sinc
hcdna
remov
effici
anionexchang
step
similar
scout
experi
sepharos
ff
ha
activ
seem
correl
total
protein
within
first
fraction
due
higher
resolut
smaller
fraction
size
howev
correl
evid
accord
profil
baselin
separ
viral
protein
host
cell
protein
could
achiev
even
lowest
load
separ
becam
wors
increas
volum
load
due
result
peak
broaden
base
result
fraction
limit
viral
prepar
defin
approxim
elut
ha
activ
recov
product
fraction
tabl
ii
start
fraction
limit
set
cv
independ
load
end
fraction
limit
calcul
accord
load
ad
cv
axial
dispers
pool
collect
fraction
assign
product
fraction
contain
elut
ha
activ
averag
amount
elut
total
protein
product
fraction
increas
load
cv
load
cv
product
increas
cv
feed
per
hour
dilut
product
decreas
yield
assum
calcul
depend
process
requir
product
need
trade
versu
puriti
optimum
clearli
depend
product
specif
case
studi
arbitrari
choic
made
select
moder
load
cv
correspond
product
cv
feed
per
hour
order
test
maximum
number
inject
regener
sec
column
becom
necessari
column
load
time
cv
viru
concentr
viru
collect
cv
elut
volum
individu
run
assign
five
group
pool
product
fraction
group
analyz
ha
activ
overlay
uv
trace
given
figur
trace
almost
indistinguish
specif
ha
activ
pool
remain
constant
within
precis
assay
unit
oper
therefor
consid
noncrit
respect
column
clean
respect
process
hygien
howev
intermedi
sanit
may
advis
particular
feed
guarante
steril
viral
prepar
column
load
multipl
time
cv
concentr
two
fraction
collect
product
wast
fraction
product
fraction
collect
cv
elut
volum
figur
scout
sec
media
column
load
volum
viru
concentr
batch
inject
eluat
fraction
coars
analyz
offlin
ha
activ
total
protein
hcdna
densiti
distribut
plot
k
av
exclus
limit
chromatographi
media
decreas
top
bottom
load
studi
sepharos
ff
column
load
volum
eluat
fraction
high
resolut
analyz
offlin
ha
activ
total
protein
uv
absorb
nm
densiti
distribut
ha
activ
protein
plot
k
av
wast
fraction
cv
typic
three
five
inject
necessari
process
one
batch
specif
ha
activ
protein
hcdna
concentr
four
independ
prepar
summar
tabl
iii
product
yield
base
ha
activ
averag
correspond
elut
ha
activ
total
recoveri
slightli
higher
averag
load
ha
activ
lost
amount
total
protein
hcdna
product
fraction
reduc
load
amount
respect
need
mention
howev
materi
balanc
protein
hcdna
typic
close
averag
total
recoveri
protein
hcdna
respect
see
discuss
two
experi
conduct
investig
stabil
ha
activ
order
find
ph
work
rang
aec
inactiv
cell
cultur
supernat
titrat
variou
ph
valu
incub
room
temperatur
differ
period
time
neutral
ha
activ
analyz
compar
fig
result
reveal
ha
activ
stabl
within
narrow
rang
ph
higher
lower
ph
degrad
occur
alkalin
condit
rate
degrad
increas
increas
ph
acid
condit
maximum
close
ph
maximum
rate
degrad
reduc
contrast
ionic
strength
tabl
ii
yield
product
dilut
sizeexclus
chromatographi
sepharos
ff
function
column
load
beyond
physiolog
condit
seem
affect
ha
activ
ad
nacl
secpurifi
viru
concentr
result
ident
ha
activ
incub
h
room
temperatur
data
shown
ionic
strength
therefor
chosen
control
adsorptiondesorpt
process
aec
two
chromatographi
media
sepharos
q
ff
sepharos
q
xl
consid
separ
hcdna
viru
nacl
alreadi
use
stabil
experi
chosen
displac
ph
stabil
use
phosphat
buffer
base
experi
hitrap
screen
column
data
shown
feed
secpurifi
viru
concentr
condit
initi
salt
concentr
nacl
column
load
cv
concentr
batch
wash
buffer
contain
nacl
linear
gradient
cv
run
nacl
flowthrough
eluat
run
fraction
analyz
offlin
ha
activ
hcdna
fig
contrast
experi
screen
column
viru
still
adsorb
anionexchang
littl
viru
flowthrough
displac
nacl
lead
elut
viru
wide
rang
salt
concentr
elut
viru
sepharos
q
xl
result
split
peak
possibl
indic
distinct
viral
popul
associ
hcdna
media
hcdna
elut
sharp
peak
overlap
part
viru
peak
higher
nacl
concentr
necessari
displac
hcdna
sepharos
q
xl
lead
better
separ
viru
respect
sepharos
q
xl
select
subsequ
experi
sinc
result
experi
screen
column
transfer
like
due
lower
concentr
viru
dna
differ
concentr
ratio
feed
materi
shorter
column
length
optimum
salt
concentr
prevent
adsorpt
viru
determin
batch
experi
sepharos
q
xl
mix
secpurifi
viru
concentr
microtit
plate
variou
salt
concentr
specif
ha
activ
hcdna
concentr
half
activ
concentr
found
column
chromatographi
ratio
howev
ident
amount
viru
ad
correspond
load
khauml
resin
incub
h
room
temperatur
sampl
taken
supernat
analyz
ha
activ
hcdna
desorb
fraction
ie
fraction
supernat
calcul
salt
concentr
ratio
ha
activ
hcdna
concentr
valu
nacl
fig
lowest
concentr
nacl
viru
adsorb
complet
stationari
phase
wherea
complet
adsorpt
hcdna
observ
concentr
nacl
concentr
viru
adsorb
prepar
run
conduct
column
column
fed
secpurifi
viru
condit
nacl
differ
amount
viru
khauml
resin
four
independ
batch
process
tabl
iv
comparison
within
one
batch
possibl
due
limit
batch
size
viru
collect
flowthrough
wherea
hcdna
possibl
impur
adsorb
stationari
phase
leakag
hcdna
order
ngml
occur
compar
mgml
feed
even
highest
load
breakthrough
hcdna
observ
consequ
data
dynam
bind
capac
column
provid
adsorb
impur
displac
step
gradient
sodium
chlorid
two
clean
solut
acid
alkalin
high
salt
solut
chromatogram
lot
contain
offlin
ha
activitiy
hcdna
data
given
figur
product
yield
base
ha
activ
seem
depend
amount
viru
load
load
greater
khauml
resin
product
yield
could
achiev
similar
result
obtain
batch
adsorpt
experi
remov
hcdna
effici
case
lead
order
magnitud
reduct
averag
amount
protein
reduc
initi
amount
sampl
product
fraction
two
independ
downstream
ultrafiltr
chromatographi
analyz
sdspage
agaros
gel
electrophoresi
sinc
result
similar
gel
sampl
one
downstream
lot
present
figur
reduct
protein
impur
origin
cell
cultur
medium
lysi
host
cell
follow
protein
gel
contrast
sever
viral
protein
enrich
among
hemagglutinin
protein
ha
approxim
kda
influenza
viru
matrix
protein
approxim
kda
could
identifi
tryptic
digest
tandem
mass
spectrometri
data
shown
high
weight
compon
kda
could
identifi
oligom
ha
neuraminidas
na
protein
indic
denatur
laemmli
buffer
incomplet
even
though
sec
use
separ
small
colloid
viru
small
protein
appear
product
fraction
sinc
sdspage
denatur
techniqu
complex
eg
virion
aggreg
broken
compon
releas
remark
small
protein
group
protein
kda
separ
sec
disappear
complet
anionexchang
step
concern
hcdna
shift
size
distribut
observ
agaros
gel
purif
sec
fragment
bp
complet
remov
maximum
intens
shift
bp
bp
sinc
similar
amount
hcdna
load
also
larger
fragment
becam
visibl
limit
detect
residu
hcdna
aec
could
visual
due
low
concentr
particl
volum
distribut
obtain
dynam
light
scatter
analysi
reveal
bimod
distribut
first
maximum
around
nm
second
maximum
vari
nm
fig
wherea
diamet
first
maximum
stabl
diamet
second
maximum
seem
increas
process
could
indic
kind
aggreg
virion
inde
analysi
viru
concentr
store
result
increas
mean
diamet
within
day
data
shown
increas
accompani
decreas
ha
activ
sec
use
separ
small
solut
colloid
viru
elut
four
chromatographi
media
led
characterist
doubl
peak
pattern
uv
trace
similar
profil
present
sepharos
ff
fig
viru
elut
first
peak
void
fraction
wherea
second
peak
result
elut
small
solut
total
inclus
like
amino
acid
nucleotid
etc
similar
elut
profil
report
human
influenza
viru
chicken
egg
heyward
et
al
equin
influenz
viru
mammlian
cell
cultur
nayak
et
al
turkey
corona
viru
tcov
propag
turkey
embryo
loa
et
al
despit
use
differ
chromatographi
media
feed
materi
case
vesicular
stomat
viru
vsvg
produc
packag
cell
line
three
peak
observ
upon
elut
sepharos
transfiguracion
et
al
studi
viru
concentr
prior
inject
noteworthi
strong
tail
viru
detect
offlinemeasur
ha
activ
observ
upon
elut
column
load
cv
secpurifi
viru
condit
nacl
lot
flowthrough
eluat
fraction
analyz
ha
activ
hcdna
eighti
percent
load
ha
activ
recov
flowthrough
hcdna
almost
complet
adsorb
stationari
phase
hcdna
desorb
step
gradient
nacl
leakag
hcdna
product
fraction
occur
sepharos
find
suggest
part
viru
popul
deterior
virion
abl
enter
fraction
pore
addit
mass
transfer
effect
due
larg
size
influenza
virion
may
enhanc
tail
elut
peak
phenomena
describ
li
et
al
use
gener
rate
model
chromatographi
strong
tail
predict
low
valu
nondimension
paramet
h
paramet
h
proport
product
pore
diffus
access
pore
volum
fraction
case
particl
close
exclus
limit
ie
low
access
pore
volum
fraction
pore
diffus
knudsen
diffus
also
low
due
diamet
ratio
particl
pore
close
uniti
thu
lead
low
valu
h
tail
elut
peak
uv
trace
complet
mislead
respect
elut
protein
hcdna
elut
mostli
two
peak
sole
indic
slight
absorb
zero
comparison
total
protein
uv
absorb
see
fig
absorb
level
two
peak
elugram
eggderiv
human
influenza
viru
heyward
et
al
tcov
loa
et
al
seem
suggest
similar
situat
hcdna
appear
slightli
larger
consequ
elut
earlier
host
cell
protein
averag
one
assum
total
protein
correl
ha
activ
viru
protein
fig
agaros
gel
electrophoresi
sampl
taken
product
fraction
prepar
sec
run
reveal
averag
hcdna
fragment
length
kb
compar
linear
dna
ladder
fragment
rang
kb
fig
potschka
report
lengthsiz
correl
r
sec
bp
nm
linear
dna
ionic
strength
mm
base
measur
calibr
sec
column
appli
correl
fragment
size
kb
translat
hydrodynam
radiu
nm
averag
radiu
influenza
virion
knipe
howley
thu
complet
separ
virion
hcdna
achiev
sizefraction
techniqu
due
separ
principl
volum
overload
sec
column
caus
peak
broaden
limit
addit
oper
restrict
rel
low
flow
rate
typic
less
cmh
order
maintain
mass
transfer
limit
accept
level
sec
oper
henc
often
pose
bottleneck
downstream
process
comparison
product
see
tabl
v
studi
high
load
cv
appli
short
column
cm
oper
rather
high
flow
rate
cmh
result
product
cvh
sixfold
higher
product
estim
heyward
et
al
eightfold
higher
product
estim
nayak
et
al
still
overal
reduct
total
protein
achiev
sec
see
signific
save
due
lower
amount
chromatographi
media
requir
due
faster
process
expect
potenti
oper
even
higher
flow
rate
thu
increas
product
explor
yet
may
done
futur
studi
viral
prepar
condit
deduc
load
studi
constantli
result
yield
tabl
iii
averag
elut
ha
activ
correspond
load
ha
activ
could
recov
product
fraction
good
agreement
origin
target
loss
load
ha
activ
explain
denatur
aggreg
nonspecif
adsorpt
virion
stationari
phase
similar
product
yield
base
ha
activ
infecti
activ
report
heyward
et
al
purif
influenza
viru
cpg
tabl
v
contrast
yield
obtain
nayak
et
al
much
lower
use
sepharos
result
strong
tail
viru
peak
also
total
recoveri
lower
compar
studi
yield
vesicular
stomat
viru
moloney
murin
leukemia
viru
purifi
sepharos
lower
respect
howev
yield
base
infect
may
less
stabl
ha
activ
averag
total
protein
could
reduc
amount
load
overal
reduct
found
sec
tabl
vi
bia
result
howev
rule
total
recoveri
protein
averag
ascrib
matrix
interfer
compon
cell
cultur
medium
found
interfer
protein
assay
sampl
supernat
concentr
compens
prepar
standard
solut
cell
cultur
medium
compens
applic
sec
eluat
fraction
howev
sinc
composit
undefin
underestim
protein
concentr
therefor
like
upon
coelut
interf
substanc
lead
total
recoveri
less
interf
substanc
assum
small
correct
estim
total
protein
concentr
would
expect
viru
eluat
fraction
underestim
wast
fraction
remain
specul
situat
hcdna
differ
total
recoveri
found
averag
contribut
nonspecif
background
fluoresc
rule
measur
appropri
blank
sampl
without
dye
contrast
repeat
measur
concentr
variou
dilut
result
slightli
higher
hcdna
concentr
higher
dilut
thu
conclud
interfer
cell
cultur
medium
compens
complet
calibr
procedur
protein
describ
consequ
underestim
hcdna
concentr
viru
concentr
occur
led
total
recoveri
henc
estim
hcdna
concentr
viru
eluat
fraction
would
correct
degre
hcdna
deplet
underestim
stabil
experi
reveal
sensit
ha
activ
acid
alkalin
ph
interestingli
degrad
fastest
around
ph
slow
toward
lower
ph
therefor
conclud
degrad
rang
unspecif
unfoald
hydrolysi
etc
occur
due
molecular
mechan
respons
endosom
membran
fusion
upon
infect
mechan
report
involv
irrevers
chang
conform
hemagglutinin
protein
trigger
low
ph
endosom
knipe
howley
similar
find
low
ph
report
scholtissek
infect
chicken
embryo
cell
infecti
allanto
fluid
impair
allanto
fluid
treat
low
ph
h
threshold
ph
investig
subtyp
report
rang
contrast
high
concentr
nacl
show
effect
ha
activ
despit
dramat
chang
osmot
pressur
possibl
explain
stabil
envelop
viral
matrix
protein
test
aec
media
sepharos
q
ff
q
xl
display
differ
select
respect
viru
hcdna
use
sepharos
q
ff
viru
hcdna
seem
separ
concentr
found
feed
possibl
separ
could
achiev
use
differ
displac
eg
hpo
etc
take
advantag
mass
transport
effect
variat
flow
rate
sinc
displac
competit
effect
reason
assum
differ
displac
may
yield
differ
select
depend
affin
resin
mobil
highli
satur
condit
hcdna
may
even
displac
viru
sinc
charg
densiti
one
neg
charg
per
base
pair
expect
much
higher
virion
laboratori
scale
howev
condit
could
achiev
amount
feed
avail
effect
flow
rate
ie
mass
transfer
effect
theori
neglig
sinc
type
colloid
dna
virion
similar
size
dna
howev
random
coil
wherea
virion
closer
rigid
sphere
specul
tentacl
protrud
dna
c
step
step
step
step
overal
yield
report
follow
unit
oper
depth
filtrat
df
microfiltr
mf
ultrafiltr
uf
sizeexclus
chromatographi
sec
anionexchang
chromatographi
aec
perform
filtrat
oper
report
previous
kalbfuss
et
al
loss
inactiv
bpropiolacton
df
mf
consid
suffici
high
load
aec
henc
averag
product
yield
similar
lot
two
four
assum
first
avail
measur
defin
turbid
measur
extinct
nm
total
protein
hcdna
measur
inactiv
final
process
yield
given
bold
type
turbidiy
b
number
process
batch
c
overal
process
yield
unit
oper
coil
may
facilit
adsorpt
even
dna
enter
pore
result
favor
adsorpt
kinet
contrast
sepharos
q
ff
partial
separ
achiev
sepharos
q
xl
split
peak
elut
viru
coelut
second
viru
peak
hcdna
howev
indic
presenc
two
distinct
popul
batch
adsorpt
experi
demonstr
similar
behavior
bimod
distribut
desorb
viru
condit
feed
nacl
result
expect
flowthrough
viru
recoveri
achiev
sepharos
q
xl
load
khauml
resin
good
agreement
batch
adsorpt
experi
nacl
reduc
yield
lower
load
like
result
residu
bind
capac
stationari
phase
satur
viru
could
recov
flowthrough
lead
high
yield
high
load
whether
ha
activ
realli
appropri
measur
load
remain
investig
averag
hcdna
reduc
amount
load
overal
reduct
order
magnitud
aec
tabl
vi
interestingli
residu
amount
hcdna
per
dose
depend
product
yield
product
yield
howev
strong
function
load
addit
split
peak
elut
result
batch
adsorpt
experi
anoth
indic
part
hcdna
associ
virion
henc
copurifi
chromatographi
similar
situt
report
konz
et
al
purifc
adenoviru
could
shown
hcdna
viruscontain
lysat
complet
digest
dnase
treatment
deterg
high
salt
buffer
report
addit
deterg
chromatographi
buffer
necessari
prevent
aggreg
virion
aggreg
could
readili
detect
dynam
light
scatter
measur
similar
aggreg
observ
product
fraction
differ
oper
fig
specul
disrupt
aggreg
would
lead
higher
puriti
less
hcdna
higher
product
yield
surprisingli
amount
total
protein
reduc
despit
high
salt
concentr
loss
explain
loss
viral
protein
case
lot
case
lot
howev
reduct
total
protein
higher
loss
ha
activ
analysi
sdspage
reveal
small
protein
group
protein
kda
remov
aec
fig
separ
behavior
protein
either
suggest
kind
hcdna
associ
highli
neg
charg
precis
calcul
product
dynam
capac
column
hcdna
would
requir
still
rough
estim
product
deriv
purpos
plasmid
purif
capac
around
mgml
resin
report
test
variou
anionexchang
ferreira
et
al
assum
hcdna
concentr
mgml
total
capac
column
calcul
cv
load
feed
maintain
constant
flow
rate
cmh
ad
h
equilibr
desorpt
clean
period
time
requir
experi
product
cv
feed
per
hour
achiev
accord
european
pharmacopeia
page
mg
hemagglutinin
antigen
per
strain
requir
one
inject
dose
human
whole
virion
vaccin
amount
total
protein
therebi
exceed
six
time
total
hemagglutinin
content
sinc
hemagglutinin
make
one
third
viral
protein
oxford
et
al
limit
correspond
protein
puriti
least
whole
virion
vaccin
regard
product
continu
cell
line
residu
level
hcdna
exceed
ng
per
dose
european
pharmacopeia
page
respect
establish
cultiv
system
kalbfuss
et
al
limit
translat
least
reduct
total
protein
order
magnitud
reduct
hcdna
assum
overal
product
yield
addit
concentr
viru
requir
vaccin
assum
contain
three
differ
viru
strain
mg
ha
antigen
volum
one
dose
exceed
ml
residu
amount
hcdna
per
dose
estim
rang
ng
tabl
iv
thu
clearli
beyond
limit
ng
unless
remov
hcdna
aec
improv
addit
oper
seem
requir
amount
total
protein
per
dose
exceed
limit
mg
assum
mg
hemagglutinin
per
dose
appar
process
fail
fulfil
requir
protein
puriti
sinc
estim
ha
concentr
ha
activ
base
number
assumpt
valu
overstress
measur
elisa
develop
indic
higher
concentr
hemagglutinin
would
expect
ha
activ
alon
one
possibl
explan
could
higher
content
hemagglutinin
cell
culturederiv
virion
support
strong
band
appear
protein
gel
fig
anoth
sourc
error
incap
ha
assay
distinguish
singl
virion
aggreg
particl
volum
distribut
strongli
suggest
presenc
latter
fig
case
analysi
srid
calibr
appropri
refer
antigen
requir
final
judgement
even
burden
host
cell
protein
turn
high
puriti
could
enhanc
time
decreas
load
sec
accept
lower
product
chromatograph
purif
concentr
cell
culturederiv
influenza
viru
result
overal
reduct
total
protein
reduct
order
magnitud
hcdna
overal
product
yield
base
ha
activ
achiev
exclud
ultradiafiltr
step
requir
final
concentr
sec
found
effici
separ
host
cell
protein
virion
puriti
howev
need
balanc
product
purpos
process
economi
reduct
hcdna
found
insuffici
respect
requir
european
pharmacopeia
optim
aec
addit
purif
step
seem
requir
far
suggest
process
scheme
remain
fulli
scalabl
free
strainspecif
unit
oper
like
immunoaffin
standard
unit
oper
common
biotechnolog
downstream
process
incorpor
render
process
suitabl
industri
largescal
product
